<DOC>
	<DOCNO>NCT02831166</DOCNO>
	<brief_summary>Primary percutaneous coronary intervention represent gold standard treatment ST-segment-elevation acute myocardial infarction . However , periprocedural bleeding associate increase risk mortality , re-infarction , stroke . Although prognostic value access site relate bleeding complication still debate , transradial approach associate well short-term outcome reduce hospital stay compare transfemoral approach . The investigator aim compare transradial approach transfemoral approach systematic achievement hemostasis implantation vascular closure device national multicentre randomize clinical trial .</brief_summary>
	<brief_title>Vascular Closure Device Versus Transradial Approach Primary Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Vascular System Injuries</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>STsegment elevation acute myocardial infarction patient first 12 hour sympton onset ; Intention perform primary percutaneous coronary intervention ; Signed informed consent ; Patient eligible transradial transfemoral primary percutaneous coronary intervention , prerequisite : ( ) familiarity operator radial femoral technique use vascular closure device , ( b ) agreement operator use access route determine randomization process . Less 18 year age ; Pregnancy ; Chronic use vitamin K antagonists direct thrombin inhibitor , oral Xafactor antagonist ; Hypersensitivity antiplatelet and/or anticoagulant drug ; Active bleeding high bleeding risk ( severe liver failure , active peptic ulcer , creatinine clearance &lt; 30 mL/min , platelet count &lt; 100.000 mm3 ) ; Uncontrolled systemic hypertension ; Cardiogenic shock ; Previous myocardial revascularization surgery â‰¥ 1 internal mammary radial artery graft ; Documented chronic peripheral arterial disease prevent use femoral technique ; Severe concomitant disease life expectancy 12 month ; Participation drug device investigative clinical trial last 30 day ; Medical , geographic social condition impair participation study inability understand sign inform consent term .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Vascular closure device</keyword>
	<keyword>Transradial approach</keyword>
	<keyword>Transfemoral approach</keyword>
</DOC>